
|Articles|November 1, 2003
New drug targets considered for erectile dysfunction
Author(s)Robert H. Carlson
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
Choosing salvage therapy after prostate cancer focal ablation
4
NDV-01 produces robust 9-month results in high-risk NMIBC
5


















